Opendata, web and dolomites

OPTOGENERAPY SIGNED

Optogenetic Protein Therapy for Multiple Sclerosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OPTOGENERAPY project word cloud

Explore the words cloud of the OPTOGENERAPY project. It provides you a very rough idea of what is the project "OPTOGENERAPY" about.

adverse    minimal    intensive    penetration    saving    losses    revolutionize    responds    device    invasiveness    engineered    porous    biomaterials    leader    implantation    prevent    neuromodulation    magazine    demands    industrial    polymeric    miniaturization    cells    validate    worldwide    subcutaneously    intravenous    barrier    offers    proposes    powered    acts    time    30    implanted    membrane    optogenetics    replacing    innovation    clear    months    implant    rejection    drug    optical    immune    peaks    multiple    synthetic    discontinuation    implants    enhanced    plans    boston    release    optogenetic    safety    technological    optimal    class    huge    sealed    gene    manufacturing    validated    treatment    cell    competitiveness    engineering    competences    scientist    meets    wireless    chamber    light    optoelectronics    adherence    electronic    market    proof    sclerosis    genexplain    prevents    autonomy    bio    biocompatibility    subcutaneous    easily    overcoming    push    2014    smes    combining    listed    cellular    ifn    therapies    efficiency    stability    micro    prototype    removed    encapsulate    least    science    optogenerapy    moulding    genetically    pull    neos    big    performance    szlig    preclinically    computer    standard    active    scientific    confinement    interferon    ultrasion    embedding   

Project "OPTOGENERAPY" data sheet

The following table provides information about the project.

Coordinator
FUNDACIO EURECAT 

Organization address
address: AVENIDA UNIVERSITAT AUTONOMA 23
city: CERDANYOLA DEL VALLES (BARCELONA)
postcode: 8290
website: www.eurecat.org/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.optogenerapy.eu
 Total cost 6˙233˙257 €
 EC max contribution 4˙777˙257 € (77%)
 Programme 1. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
 Code Call H2020-NMBP-2016-two-stage
 Funding Scheme RIA
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2020-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO EURECAT ES (CERDANYOLA DEL VALLES (BARCELONA)) coordinator 1˙256˙557.00
2    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 951˙345.00
3    BOSTON SCIENTIFIC LIMITED IE (GALWAY) participant 805˙880.00
4    GENEXPLAIN GMBH DE (WOLFENBUTTEL) participant 386˙100.00
5    ERASMUS UNIVERSITEIT ROTTERDAM NL (ROTTERDAM) participant 322˙590.00
6    NEOS SURGERY SL ES (DONOSTIA SAN SEBASTIAN) participant 303˙375.00
7    POLITECHNIKA LODZKA PL (LODZ) participant 255˙000.00
8    TWOPTICS SYSTEMS DESIGN SL ES (BARCELONA) participant 246˙410.00
9    ULTRASION S.L. ES (CERDANYOLA DEL VALLES) participant 172˙500.00
10    ASOCIACION ESPANOLA DE NORMALIZACION ES (MADRID) participant 77˙500.00
11    EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH CH (ZUERICH) participant 0.00

Map

 Project objective

Optogenerapy proposes a new interferon-ß (IFN-ß) drug delivery system to revolutionize Multiple Sclerosis treatment.

The aim is to develop and validate a new bio-electronic cell based implant device to be implanted subcutaneously providing controlled drug release during at least 6 months. The cell confinement within a chamber sealed by a porous membrane allows the device to be easily implanted or removed. At the same time, this membrane acts to prevent immune rejection and offers long-term safety in drug release while overcoming the adverse effects of current cellular therapies. Wireless powered optogenetics – light controlling the cellular response of genetically engineered cells – is used to control the production of IFN-ß.

Replacing standard intravenous IFN-ß delivery by subcutaneous delivery prevents short and long term side effects and efficiency-losses related to drug peaks and discontinuation, while saving non-adherence costs.

It is a low-cost system enabling large scale manufacturing and reduction of time to market up to 30% compared to other cell therapies, combining: - Polymeric biomaterials with strong optical, biocompatibility and barrier requirements, to build the cell chamber and to encapsulate the optoelectronics. - Optoelectronics miniaturization, autonomy and optical performance. - Optimal cellular engineering design, enhanced by computer modelling, for stability and performance of the synthetic optogenetic gene pathway over long-term implantation. - Micro moulding enabling optoelectronics and membrane embedding for safety and minimal invasiveness.

The innovation potential is so huge that a proof-of-concept was listed by Scientist Magazine as one of the 2014’s big advances in science.

In our top-class consortium, industrial pull meets technological push, ensuring that the preclinically validated prototype obtained at the end responds to market demands.

BOSTON SCIENTIFIC, worldwide leader in neuromodulation active implants, has clear exploitation plans and high market penetration potential. 4 research intensive SMEs: TWO, GENEXPLAIN, NEOS and ULTRASION bring specific competences while increasing their own competitiveness.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OPTOGENERAPY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OPTOGENERAPY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.3.)

SMARTFAN (2018)

Smart by Design and Intelligent by Architecture for turbine blade fan and structural components systems

Read More  

ReSHEALience (2018)

Rethinking coastal defence and Green-Energy Service infrastructures through enHancEd-durAbiLIty high-performance fiber reinforced cement-based materials.

Read More  

SYNAMERA (2015)

Synergies in Nanotechnologies, Materials and Production in the European Research Area

Read More